NA Travel Vaccine Market - Industry Trends and Forecast to 2035

NA Travel Vaccine Market - Industry Trends and Forecast to 2035

North America travel vaccine market is expected to reach USD 3,999,023.57 thousand by 2032 from USD 1,743,097.85 thousand in 2023, growing at a substantial CAGR of 9.8% in the forecast period of 2024 to 2032.

Market Segmentation:

By Composition (Combination Vaccines and Mono Vaccines), Type (Inactivated Vaccines, Subunit, Recombinant, Polysaccharide and Conjugate Vaccines, Live-Attenuated Vaccines, Toxoid Vaccines, DNA Vaccines, and Viral Vector Vaccines), Category (Recommended Vaccine, Routine Vaccine and Required Vaccine), Disease (Typhoid, Hepatitis, Cholera, Varicella, Influenza, Japanese Encephalitis, Meningococcal Meningitis, Yellow Fever, Rabies, DPT, Measles and Mumps, Tick-Borne Encephalitis, Malaria, Covid-19, Polio and Others), Route of Administration (Injectable and Oral), Gender (Male and Female), Patient Type (Adult, Pediatric and Geriatric), Age Group (20-50 Years, Less than 20 Years and Above 50 Years), Distribution Channel (B2B and B2C), Countries (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2032

Some of the major factors contributing to the growth of the North America travel vaccines market are:

Driver
• Rising incidence of infectious diseases
Restraint
• High cost of travel vaccines
Opportunity
• Advancements in vaccine technology
Market Players
Some major companies dealing in the North America travel vaccines market are:
• GSK plc.
• Bavarian Nordic
• Pfizer Inc.
• Abbott
• CSL
• AstraZeneca
• Sanofi
• Merck & Co., Inc.
• Valneva SE
• Johnson & Johnson Services Inc.
• Dynavax Technologies.


Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.